Swiss drugmaker Roche is buying U.S.-based Jecure Therapeutics, joining Pfizer, Gilead Sciences and Novartis in pursuit of new drugs to treat fatty liver disease.
A leading provider of network-enabled services for hospital and ambulatory customers nationwide, Veritas Capital ("Veritas") and Evergreen Coast Capital ("Evergreen"), today announced that they have entered into a definitive agreement under which an affiliate of Veritas and Evergreen will acquire athenahealth for approximately $5.7 billion in cash.
Discovery Ltd.’s successful 1.85 billion-rand ($131 million) bookbuild puts it on the threshold of starting its banking unit.
Ziylo and Novo Nordisk A/S today announced that Novo Nordisk has acquired all of the shares of Ziylo, a University of Bristol spin-out company based at Unit DX science incubator in Bristol, UK. Ziylo has been pioneering the use of its platform technology - synthetic glucose binding molecules - for therapeutic and diagnostic applications.
Gilead Sciences Inc. is being roiled by executive departures a year after placing a big bet on the hot world of cancer immunotherapy with its purchase of Kite Pharma.
William Wrigley Jr. II, who helped orchestrate the sale of his family’s business to Mars Inc. in 2008, led a $65 million investment round for Surterra Wellness, a medical cannabis startup in Georgia with licenses to operate in Florida and Texas. The funding brings the total raised so far to $100 million, according to Surterra.
Linde AG shares fell the most in a year after the U.S. antitrust regulator raised an unexpected hurdle to the company’s $42 billion merger with Praxair Inc. that could derail the deal to create the world’s largest industrial gas producer.